Vistagen Therapeutics, Inc. (VTGN)

Vistagen Therapeutics, Inc.'s stock price was significantly impacted by the failure of the PALISADE-3 Phase 3 study for fasedienol, leading to a dramatic decline in the company's stock price. Other factors include persistent financial losses, increased R&D expenses, and substantial dilution of shares. The company reported a net loss of -$67.05 million and a loss per share of -$1.89 over the last 12 months, with R&D expenses increasing to $14.2 million for the three months ending December 31, 2025. Additionally, a securities class action lawsuit has been initiated, and shares declined 7.2% the day following the last earnings report on February 12, 2026.

Based on historical stock price data, August has historically shown the highest probability of positive returns for Vistagen Therapeutics, Inc., while July has the lowest, and April also suggests it may not be an ideal month to invest.

Vistagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for anxiety, depression, and other central nervous system disorders, utilizing a nose-to-brain neurocircuitry approach with intranasal product candidates called pherines. The company's pipeline includes Fasedienol (PH94B), Itruvone (PH10), AV-101, PH15, PH80, and PH284. Fasedienol is in preparation for Phase 3 development for social anxiety disorder. PH10 is being investigated for major depressive disorder. AV-101 is being evaluated for neuropsychiatric and neurological indications, including MDD and neuropathic pain.

Vistagen Therapeutics, Inc. is headquartered in South San Francisco, California, and focuses its development and commercialization strategies primarily on North America and Asia. The company has a licensing and collaboration agreement with EverInsight Therapeutics for PH94B in Greater China, South Korea, and Southeast Asia.

Vistagen Therapeutics, Inc.'s reputation has been negatively affected by the failure of the PALISADE-3 Phase 3 clinical trial for fasedienol and the securities class action lawsuit.

Vistagen Therapeutics, Inc. has 61 institutional owners and shareholders holding a total of 11,354,849 shares, including Orbimed Advisors Llc, Vanguard Group Inc, and BlackRock, Inc. Venrock Healthcare Capital Partners II LP is the largest individual shareholder, owning 52.09% of the company.